Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications

License gives Santhera worldwide rights to vamorolone, now also including the major markets Japan and South Korea, and paves the way for partnering in additional indicationsAgreements with Idorsia and ReveraGen give Santhera immediate control over vamorolone and defer milestone-related payments